What does Genflow Biosciences do?

Genflow Biosciences is a research organisation in Charleroi. Private Limited, started on 10 September 2020, 1 establishment.

What is the address of Genflow Biosciences?

The registered office of Genflow Biosciences is located at Rue Auguste Piccard 48, 6041 Charleroi.

Is Genflow Biosciences still active?

Yes. According to the CBE (29 October 2026) Genflow Biosciences is active, legal situation “Normale toestand”, started on 10 September 2020.

Is Genflow Biosciences registered on Peppol?

Yes, Genflow Biosciences is registered on the Peppol network with ID 0208:0753904685.

What is the enterprise number of Genflow Biosciences?

The enterprise number of Genflow Biosciences is BE0753904685.

When was Genflow Biosciences founded?

Genflow Biosciences was founded on 10 September 2020.

Who are the directors of Genflow Biosciences?

According to the 2025 annual accounts, the directors of Genflow Biosciences are: Eric Leire.

Is Genflow Biosciences a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 10 September 2020; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Genflow Biosciences make in 2025?

Genflow Biosciences recorded a loss after taxes of € 267,933 in financial year 2025.

What is the revenue of Genflow Biosciences?

As a small company, Genflow Biosciences is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -264,246.

How many employees does Genflow Biosciences have?

According to the 2025 annual accounts, Genflow Biosciences has 0 full-time equivalents (FTE).

Genflow Biosciences (Private Limited) - Charleroi

Dossier Genflow Biosciences, printed on 29 October 2026 from databakkes.be/en/0753904685/genflow-biosciences. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 12 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

Genflow Biosciences from Charleroi, company number BE0753904685, closed financial year 2025 with a result of € -267,932 after tax. For that financial year Genflow Biosciences recorded a gross margin of € -264,246 and equity of € 896,515. Compared with financial year 2024, the result moved from € -324,575 to € -267,932. The company made a loss. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.

What it is worth Growing

€ 896,515

▲ 49% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -267,932

▲ 17 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 27,082

▼ 88% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -948,560.

People and assets in 2025

Full-time equivalents

Average over the fiscal year, from the social balance sheet.

Vehicles and equipment

€ 1,225

▼ 51% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 6,241

▲ € 6,097 vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 750,884

▲ 14% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 20,030

▲ 19% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -505,892 Gross margin 2022: € -505,892 First fiscal year in the series	€ -1,148,031 Gross margin 2023: € -1,148,031 ▼ € 642,139 vs 2022 (€ -505,892) Unfavourable step	€ -282,434 Gross margin 2024: € -282,434 ▲ € 865,597 vs 2023 (€ -1,148,031) Favourable step	€ -264,246 Gross margin 2025: € -264,246 ▲ € 18,188 vs 2024 (€ -282,434) Favourable step	▲ € 18,188
Profit after taxes	€ -508,935 Profit after taxes 2022: € -508,935 First fiscal year in the series	€ -1,156,052 Profit after taxes 2023: € -1,156,052 ▼ € 647,117 vs 2022 (€ -508,935) Unfavourable step	€ -324,575 Profit after taxes 2024: € -324,575 ▲ € 831,477 vs 2023 (€ -1,156,052) Favourable step	€ -267,932 Profit after taxes 2025: € -267,932 ▲ € 56,642 vs 2024 (€ -324,575) Favourable step	▲ € 56,642
Equity	€ -807,401 Equity 2022: € -807,401 First fiscal year in the series	€ 530,377 Equity 2023: € 530,377 ▲ € 1.3 million vs 2022 (€ -807,401) Favourable step	€ 602,186 Equity 2024: € 602,186 ▲ 14% vs 2023 (€ 530,377) Favourable step	€ 896,515 Equity 2025: € 896,515 ▲ 49% vs 2024 (€ 602,186) Favourable step	▲ 49%
Total debts	€ 2,168,313 Total debts 2022: € 2,168,313 First fiscal year in the series	€ 395,705 Total debts 2023: € 395,705 ▼ 82% vs 2022 (€ 2,168,313) Favourable step	€ 1,636,319 Total debts 2024: € 1,636,319 ▲ € 1.2 million vs 2023 (€ 395,705) Unfavourable step	€ 2,840,284 Total debts 2025: € 2,840,284 ▲ 74% vs 2024 (€ 1,636,319) Unfavourable step	▲ 74%
Cash	€ 797,474 Cash 2022: € 797,474 First fiscal year in the series	€ 503,501 Cash 2023: € 503,501 ▼ 37% vs 2022 (€ 797,474) Unfavourable step	€ 218,305 Cash 2024: € 218,305 ▼ 57% vs 2023 (€ 503,501) Unfavourable step	€ 27,082 Cash 2025: € 27,082 ▼ 88% vs 2024 (€ 218,305) Unfavourable step	▼ 88%
Retained profit	€ -827,301 Retained profit 2022: € -827,301 First fiscal year in the series	€ -356,052 Retained profit 2023: € -356,052 ▲ € 471,249 vs 2022 (€ -827,301) Favourable step	€ -680,627 Retained profit 2024: € -680,627 ▼ € 324,575 vs 2023 (€ -356,052) Unfavourable step	€ -948,560 Retained profit 2025: € -948,560 ▼ € 267,933 vs 2024 (€ -680,627) Unfavourable step	▼ € 267,933
Bank debt	€ 1,787 Bank debt 2022: € 1,787 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 1,787) Favourable step	€ 144 Bank debt 2024: € 144 Unchanged (€ 0) Unfavourable step	€ 6,241 Bank debt 2025: € 6,241 ▲ € 6,097 vs 2024 (€ 144) Unfavourable step	▲ € 6,097
Balance sheet total	€ 1,360,912 Balance sheet total 2022: € 1,360,912 First fiscal year in the series	€ 926,082 Balance sheet total 2023: € 926,082 ▼ 32% vs 2022 (€ 1,360,912) Unchanged	€ 2,238,505 Balance sheet total 2024: € 2,238,505 ▲ 142% vs 2023 (€ 926,082) Unchanged	€ 3,736,799 Balance sheet total 2025: € 3,736,799 ▲ 67% vs 2024 (€ 2,238,505) Unchanged	▲ 67%

Key figures of Genflow Biosciences, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Genflow Biosciences?

What happened at Genflow Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 31, 2026 New annual accounts for financial year 2025: loss of € 267,933. Source: NBB ↗
Sep 10, 2020 New establishment in Charleroi. KBO
2020 Eric Leire became a director. NBB
Sep 10, 2020 Start of the company according to the CBE. KBO

In short

From € 508,935 loss in 2022 to € 267,933 loss in 2025.

Original PDFs at the National Bank ↗

Management

Eric Leire

Genflow Biosciences

Behind Genflow Biosciences is Eric Leire.

Directors

According to the 2025 annual accounts

Eric Leire

Director

since 2020

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Auguste Piccard 48

6041 Charleroi

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 6 companies are registered at this address.

All companies at this address →

SYNABS

€ 742,551 gross margin · 2025

European Infrared Technologies

€ 53,354 gross margin · 2024

HEARTKINETICS

€ -463,720 gross margin · 2022

NEUVASQ BIOTECHNOLOGIES

€ 641,586 gross margin · 2025

CANCER STATE THERAPEUTICS

€ -105,252 gross margin · 2025

+1 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0753.904.685
VAT number: BE 0753.904.685
Registered office: Rue Auguste Piccard 48, 6041 Charleroi
Names & denominations: Genflow Biosciences
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 10 September 2020
Peppol: Active · Active since 18 Mar 2025
Activities · NACE: Speur- en ontwikkelingswerk op biotechnologisch gebied

View on CBE Public ↗ Annual accounts (NBB) ↗